Payment overview · 2025
General Payments
$734.21
13 reported records · 7 companies
Healthcare provider profile · identity verified
Michael J Manuel, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · FINDLAY, OH · NPI 1801873641
Verified facts
What the public records show
CMS Open Payments records show Michael J Manuel, M.D. received $734.21 in general payments during 2025 across 13 reported records.
Kerecis Limited accounted for 56.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lumigan by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Kerecis Limited | Unresolved — no canonical attribution shown | $415.28 | 56.6% | 6 | 2025 |
| Access Pro Medical, LLC | Unresolved — no canonical attribution shown | $153.43 | 20.9% | 1 | 2025 |
| MIMEDX Group, Inc. | Unresolved — no canonical attribution shown | $60.58 | 8.2% | 2 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $43.52 | 5.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $22.42 | 3.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.98 | 2.7% | 1 | 2025 |
| Urgo Medical North America, LLC | Unresolved — no canonical attribution shown | $19.00 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $417.30 | 12 |
| Education | $316.91 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $415.28 | 6 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $415.28 | 6 | 2025 |
Source payment records
|
|||||
| MATRIDERM Normalized: matriderm |
Device | Access Pro Medical, LLC | $153.43 | 1 | 2025 |
Source payment records
|
|||||
| RENASYS GO v2 HOME Normalized: renasys go v2 home |
Device | Smith+Nephew, Inc. | $43.52 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $22.42 | 1 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $19.98 | 1 | 2025 |
Source payment records
|
|||||
| URGOCLEAN AG Normalized: urgoclean ag |
Device | Urgo Medical North America, LLC | $19.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 53 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 536 | 104 |
| Eliquis | Apixaban | 385 | 64 |
| Levothyroxine Sodium | Levothyroxine Sodium | 382 | 73 |
| Metoprolol Tartrate | Metoprolol Tartrate | 324 | 59 |
| Amlodipine Besylate | Amlodipine Besylate | 310 | 58 |
| Potassium Chloride | Potassium Chloride | 306 | 59 |
| Furosemide | Furosemide | 272 | 59 |
| Memantine Hcl | Memantine Hcl | 256 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 248 | 44 |
| Sertraline Hcl | Sertraline Hcl | 243 | 38 |
| Omeprazole | Omeprazole | 240 | 45 |
| Donepezil Hcl | Donepezil Hcl | 232 | 30 |
| Gabapentin | Gabapentin | 206 | 42 |
| Lisinopril | Lisinopril | 206 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 199 | 30 |
| Trazodone Hcl | Trazodone Hcl | 196 | 46 |
| Clopidogrel | Clopidogrel Bisulfate | 185 | 24 |
| Mirtazapine | Mirtazapine | 168 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 164 | 41 |
| Famotidine | Famotidine | 150 | 27 |
| Losartan Potassium | Losartan Potassium | 148 | 35 |
| Buspirone Hcl | Buspirone Hcl | 126 | 20 |
| Allopurinol | Allopurinol | 117 | 27 |
| Levetiracetam | Levetiracetam | 114 | 16 |
| Simvastatin | Simvastatin | 111 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 97 | 15 |
| Metformin Hcl | Metformin Hcl | 96 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 83 | 19 |
| Baclofen | Baclofen | 80 | 21 |
| Xarelto | Rivaroxaban | 80 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 78 | 16 |
| Carvedilol | Carvedilol | 75 | 21 |
| Oxybutynin Chloride | Oxybutynin Chloride | 75 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 72 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 63 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 62 | 13 |
| Alendronate Sodium | Alendronate Sodium | 57 | 14 |
| Bumetanide | Bumetanide | 56 | 19 |
| Finasteride | Finasteride | 56 | suppressed |
| Levofloxacin | Levofloxacin | 56 | 38 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 54 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 54 | suppressed |
| Rexulti | Brexpiprazole | 53 | suppressed |
| Myrbetriq | Mirabegron | 52 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 51 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 51 | 14 |
| Farxiga | Dapagliflozin Propanediol | 51 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 50 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 49 | 11 |
| Sucralfate | Sucralfate | 49 | suppressed |
| Prednisone | Prednisone | 48 | 16 |
| Spironolactone | Spironolactone | 47 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 46 | 19 |
| Atenolol | Atenolol | 43 | suppressed |
| Januvia | Sitagliptin Phosphate | 43 | suppressed |
| Latanoprost | Latanoprost | 43 | 13 |
| Cephalexin | Cephalexin | 42 | 16 |
| Levemir Flexpen | Insulin Detemir | 42 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 40 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 37 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 36 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 34 | 11 |
| Jardiance | Empagliflozin | 34 | suppressed |
| Nystatin | Nystatin | 34 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 31 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 21 |
| Lovastatin | Lovastatin | 29 | suppressed |
| Valsartan | Valsartan | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Glimepiride | Glimepiride | 27 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 27 | suppressed |
| Alprazolam | Alprazolam | 26 | 13 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 26 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 26 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 26 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 26 | suppressed |
| Risperidone | Risperidone | 26 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 25 | suppressed |
| Hydrocortisone | Hydrocortisone | 24 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 23 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 15 |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 22 | suppressed |
| Calcitriol | Calcitriol | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 13 |
| Glipizide | Glipizide | 22 | suppressed |
| Nystop | Nystatin | 22 | 16 |
| Insulin Aspart Flexpen | Insulin Aspart | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 16 |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 16 |
| Galantamine Hbr | Galantamine Hbr | 18 | suppressed |
| Valium | Diazepam | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Procto-Med Hc | Hydrocortisone | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Zonisamide | Zonisamide | 16 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Calcium Acetate | Calcium Acetate | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 15 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 15 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 15 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 15 | suppressed |
| Timolol Maleate | Timolol Maleate | 15 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 15 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Nadolol | Nadolol | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 13 | suppressed |
| Isosorbide Dinit-Hydralazine | Isosorbide Dinit/Hydralazine | 13 | suppressed |
| Letrozole | Letrozole | 13 | suppressed |
| Meloxicam | Meloxicam | 13 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 12 | suppressed |
| Galantamine Er | Galantamine Hbr | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Zafirlukast | Zafirlukast | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Lumigan | Bimatoprost | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $734.21 · 13 records | Kerecis Limited | DALVANCE, Kerecis GraftGuide, Kerecis SurgiClose, MATRIDERM, RENASYS GO v2 HOME, REXULTI, URGOCLEAN AG | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rexulti play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error